XASECYBN
Market cap189mUSD
Dec 24, Last price
9.49USD
1D
-0.52%
1Q
-8.22%
IPO
387.77%
Name
Cybin Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-9.78%
Rev. gr., 5y
%
Revenues
0k
Net income
-78m
L+95.02%
CFO
-69m
L+52.43%
Profile
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑07 | 2018‑07 | 2017‑07 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 65,374 | 51,769 | 64,006 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (65,374) | (51,769) | (64,006) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (7,453) | 3,793 | ||||||
Tax Rate | ||||||||
NOPAT | (65,374) | (44,316) | (67,799) | |||||
Net income | (78,080) 95.02% | (40,037) -43.94% | (71,424) 121.68% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 254,600 | 31,507 | 35,777 | |||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | 291 | |||||||
Deferred revenue | ||||||||
Other long-term liabilities | 5,262 | 1,094 | ||||||
Net debt | (208,701) | (53,883) | (64,268) | |||||
| Cash flow | ||||||||
Cash from operating activities | (68,908) | (45,207) | (19,027) | |||||
CAPEX | (21) | (520) | (231) | |||||
Cash from investing activities | 6,922 | (770) | (1,189) | |||||
Cash from financing activities | 254,507 | 35,777 | 35,777 | |||||
FCF | (65,430) | (44,250) | (66,859) | |||||
| Balance | ||||||||
Cash | 208,992 | 53,641 | 64,026 | |||||
Long term investments | 242 | 242 | ||||||
Excess cash | 208,992 | 53,883 | 64,268 | |||||
Stockholders' equity | 280,177 | 40,424 | 67,670 | |||||
Invested Capital | 82,935 | 35,731 | 22,944 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 8,299 | 185,429 | 167,287 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (64,950) | (51,601) | (63,957) | |||||
EV/EBITDA | ||||||||
Interest | 7,453 | 241 | ||||||
Interest/NOPBT | ||||||||